

Venlafaxine (Effexor®)

Selected References:

- Anderson KN, et al., 2020. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. *JAMA psychiatry*, 77(12):1246-1255.
- Bellantuono C, et al. 2015. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. *Hum Psychopharmacol*. 30(3):143-51.
- Berard A, et al. 2017. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: An updated analysis of the Quebec Pregnancy Cohort. *BMJ Open*;7: e013372.
- Berle JO, et al. 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. *J Clin Psychiatry*. 65(9):1228-1234.
- Chambers CD, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med*. 354:579-587.
- Dandjinou M, et al. 2019. Antidepressant use during pregnancy and risk of gestational diabetes mellitus: a nested case-control study. *BMJ Open* 9(9): e025908.
- Das N, Chadda RK. 2020. Hyperprolactinemic galactorrhea associated with cefpodoxime in a patient with recurrent depressive disorder on venlafaxine monotherapy: A case report. *J Clin Psychopharmacol*. 40:635-6.
- Desai PH, et al. 2019. Risk of congenital heart disease in newborns with prenatal exposure to anti-depressant medications. *Cureus* 11(5): e4673.
- de Santi F, et al. 2021. Venlafaxine-induced damage to seminiferous epithelium, spermiation, and sperm parameters in rats: A correlation with high estrogen levels. *Andrology*. 9(1):297-311.
- Einarson A, et al. 2001. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. *Am J Psychiatry*. 158(10):1728-1730.
- Ferreira E, et al. 2007. Effects of selective reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. *Pediatrics*. 119(1):52-59.
- Furu K, et al. 2015. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. *BMJ*. 350:h1798.
- Grzeskowiak LE, et al. 2022. Perinatal antidepressant use and breastfeeding outcomes: Findings from the Norwegian Mother, Father and Child Cohort Study. *Acta Obstet Gynecol Scand*. 101:344-54
- Grigoriadis S, et al. 2013. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. *J Clin Psychiatry*. 74(4): e309-20.
- Holland J, Brown R. 2017. Neonatal venlafaxine discontinuation syndrome: A mini-review. *Eur J Paediatr Neurol*. 21(2):264-8.
- Ilett KF, et al. 2002. Distribution of venlafaxine and its o-desmethyl metabolite in human milk and their effects in breastfed infants. *Br J Clin Pharmacol*. 53:17-22.
- Kieviet N, et al. 2015. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. *Acta Paediatr*. 104(4):384-91.
- Kolding L, et al. 2021. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study. *BJOG* 128(12):1949-1957.
- Lassen D, et al., 2016. First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: A systematic review. *Basic Clin Pharmacol Toxicol*. 118(1):32-6.
- Lennestall R and Kallen B. 2007. Delivery outcome in relation to maternal use of some recently introduced antidepressants. *J Clin Psychopharmacol*. 27(6):607-613.
- Levinson-Castiel R, et al. 2006. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. *Arch Pediatr Adolesc Med*. 160:173-176.

- Marks C, et al. 2021. Comparing newborn outcomes after prenatal exposure to individual antidepressants: A retrospective cohort study. *Pharmacotherapy*. 41(11):907-914.
- Matthys A, et al. 2014. Psychotropic medication use during pregnancy and lactation: Role of ultrasound assessment. *Donald Sch J Ultrasound Obstet Gynecol*. 8:109-21.
- Newport DJ, et al. 2009. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. *J.Clin Psychiatry*. 70(9):1304-10.
- Newport DJ, et al. 2016. Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy. *J Clin Psychiatry*. 77(11):1538-45.
- Nulman I, et al. 2012. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. *Am J Psychiatry*. 169(11):1165-74.
- Polen KN, et al., National Birth Defects Prevention Study. 2013. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. *Birth Defects Res A Clin Mol Teratol*. 97(1):28-35.
- Rai D, et al. 2017. Antidepressants during pregnancy and autism in offspring: population-based cohort study. *BMJ* 358:j2811,
- Richardson JL, et al. 2019. Pregnancy outcomes following maternal venlafaxine use: a prospective observational comparative cohort study. *Reprod Toxicol* 84:108-113,
- Schoretsanitis G, et al. 2019. Antidepressants in breastmilk: comparative analysis of excretion ratios. *Arch Womens Ment Health* 22(3):383-390.
- U.S. Food and Drug Administration. 2023. Effexor XR Drug Label. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf. Accessed 5 March 2026.
- Wang XY, et al. 2023. Antidepressant use during pregnancy and the risk for gestational diabetes: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med* 36(1):2162817,
- Wartko PD, et al. 2019. Antidepressant continuation in pregnancy and risk of gestational diabetes. *Pharmacoepidemiol Drug Saf* 28(9): 1194-1203.
- Westin AA, et al. 2017. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. *PLoS One*. 12(7):e0181082.
- Yue M, et al. 2023. Pharmacokinetics of Antidepressants in Pregnancy. *J Clin Pharmacol*. 63 Suppl 1: S137-S158.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Venlafaxine (Effexor®)

Selected References:

- Adeniyi AA, et al. 2024. Oral Health, Anxiety, Depression, and Stress in Pregnancy: A Rapid Review of Associations and Implications for Perinatal Care. *Int J Environ Res Public Health*. 22(1):32.
- American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders, 5th ed. American Psychiatric Association, Washington, DC.
- Anderson PO. 2024. Anxiety Disorders and Breastfeeding. *Breastfeed Med*. 19(3):152-154.
- Arvanitidou O, et al. 2023. The Impact of Stress and Depression on the Outcome of Human Gestation. *Cureus*.15(11):e48700.
- Bhongade M, et al. 2015. Effect of psychological stress on fertility hormones and seminal quality in male partners of infertile couples. *Andrologia*. 47(3):336-342.
- Bodunde EO, et al. 2025. Pregnancy and birth complications and long-term maternal mental health outcomes: A systematic review and meta-analysis. *BJOG*.132(2):131-142.
- Bolea-Alamañac B, et al. 2018. Do mothers who are anxious during pregnancy have inattentive children? *J Affect Disord*. 236:120-126.
- Clinkscales N, et al. 2023. The effectiveness of psychological interventions for anxiety in the perinatal period: A systematic review and meta-analysis. *Psychol Psychother*. 96(2):296-327.
- Dabb C, et al. 2023. Paternal pregnancy-related anxiety: Systematic review of men's concerns and experiences during their partners' pregnancies. *J Affect Disord*. 323:640-658.
- Dean DC, et al. 2018. Association of prenatal maternal depression and anxiety symptoms with infant white matter microstructure. *JAMA Pediatr*. 172(10):973-981.
- Ding X-X, et al. 2014. Maternal anxiety during pregnancy and adverse birth outcomes: A systematic review and meta-analysis of prospective cohort studies. *J Affect Disord*. 159:103-110.
- Dunkel Schetter C, et al. 2022. Anxiety in pregnancy and length of gestation: Findings from the healthy babies before birth study. *Health psychology: official journal of the Division of Health Psychology, American Psychological Association* 41(12):894-903.
- George A, et al. 2013. Anxiety symptoms and coping strategies in the perinatal period. *BMC Pregnancy and Childbirth*. 13:233.
- Gimbel LA, et al. 2022. Pregnancy outcomes and anxiety in nulliparous women. *J Matern Fetal Neonatal Med*. 35(25):8681-8690.
- Göbel A, et al. 2018. The association between maternal-fetal bonding and prenatal anxiety: An explanatory analysis and systematic review. *J Affect Disord*. 239:313-327.
- Goodman J, et al. 2014. Anxiety disorders during pregnancy: A systematic review. *J Clin Psychiatry*. 75(10):e1153-e1154.
- Grigoriadis S, et al. 2018. Maternal Anxiety During Pregnancy and the Association with Adverse Perinatal Outcomes: Systematic Review and Meta-Analysis. *J Clin Psychiatry*. 79(5):17r12011.
- Hadfield K, et al. 2022. Measurement of pregnancy-related anxiety worldwide: a systematic review. *BMC Pregnancy Childbirth*. 22(1):331.
- Koerner A, et al. 2024. Are Providers Adequately Screening for Anxiety Symptoms During Pregnancy? *Nurs Womens Health*. 28(2):109-116.
- Korja R, et al. 2024. Trajectories of maternal depressive and anxiety symptoms and child's socio-emotional outcome during early childhood. *J Affect Disord*. 349:625-634.

- Magnus MC, et al. 2021. Risk of miscarriage in women with psychiatric disorders. *Br J Psychiatry*. 219(3):501-506.
- Malm H, et al. 2015. Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: Results from population-based National Register data. *Am J Psychiatry*. 172(12):1224-1232.
- Misri S, et al. 2015. Perinatal generalized anxiety disorder: assessment and treatment. *J Womens Health (Larchmt)*. 24(9):762-770.
- Mughal MK, et al. 2019. Trajectories of maternal distress and risk of child developmental delays: Findings from the All Our Families (AOF) pregnancy cohort. *J Affect Disord*. 248:1-12.
- Navaratne P, et al. 2016. Impact of a high Edinburgh Postnatal Depression Scale score on obstetric and perinatal outcomes. *Sci Rep*. 6:33544.
- Ossola P, et al. 2021. Anxiety, depression, and birth outcomes in a cohort of unmedicated women. *J Matern Fetal Neonatal Med*; 34(10):1606-1612.
- Pan Y, et al. 2022. Association between generalized anxiety symptoms and semen quality in infertile men: A multicentre study in North China. *Andrologia*. 54(8):e14449. Pavlov M, et al. 2014. Obstetric and neonatal outcome in patients with anxiety disorders. *J Matern Fetal Neonatal Med*. 27:(13) 1339-1342.
- Pezley L, et al. 2022. Efficacy of behavioral interventions to improve maternal mental health and breastfeeding outcomes: a systematic review. *Int Breastfeed J*. 17(1):67.
- Purkiewicz A, et al. 2025. Breastfeeding: The Multifaceted Impact on Child Development and Maternal Well-Being. *Nutrients*. 17(8):1326.
- Ramos I, et al. 2022. Pregnancy anxiety, placental corticotropin-releasing hormone and length of gestation. *Biol Psychol*. 172:108376.
- Ravid E, et al. 2018. Is there an association between maternal anxiety propensity and pregnancy outcomes? *BMC Pregnancy Childbirth*. 18(1):287.
- Rogers A, et al. 2020. Association Between Maternal Perinatal Depression and Anxiety and Child and Adolescent Development: A Meta-analysis. *JAMA Pediatr*. 174(11):1082-1092.
- Rooney KL, Domar AD. 2018. The relationship between stress and infertility. *Dialogues Clin Neurosci*. 20(1):41-47.
- Salehi F, et al. 2016. Comparison of group cognitive behavioral therapy and interactive lectures in reducing anxiety during pregnancy: A quasi experimental trial. *Medicine (Baltimore)*. 95(43):e5224.
- Schetter CD, et al. 2022. Anxiety in pregnancy and length of gestation: Findings from the healthy babies before birth study. *Health Psychol*. 41(12):894-903. Shi Y, Han
- Q. 2024. Does maternal anxiety and depression increase the risk of asthma in the offspring? A systematic review and meta-analysis. *Eur Rev Med Pharmacol Sci*. 28(3):1066-1076.
- Smith CA, et al. 2019. The effect of complementary medicines and therapies on maternal anxiety and depression in pregnancy: A systematic review and meta-analysis. *J Affect Disord*. 245:428-439.
- Veleminsky M, et al. 2024. Depression and Anxiety. Depression and anxiety in women during physiological pregnancy. *Neuro Endocrinol Lett*. 45(7-8):523-538.
- Yang Z, et al. 2023. Trajectory of prenatal anxiety and depression and its association with fetal growth development. *Early Hum Dev*. 187:105875.
- Yonkers KA, et al. 2017. Association of panic disorder, generalized anxiety disorder, and benzodiazepine treatment during pregnancy with adverse birth outcomes. *JAMA Psychiatry*. 74(11):1145-1152.
- Zhang T, et al. 2023. The impact of maternal depression, anxiety, and stress on early neurodevelopment in boys and girls. *J Affect Disord*. 321:74-82.
- Zhou J, et al. 2023. Maternal anxiety during pregnancy and children's asthma in preschool age: The Ma'anshan birth cohort study. *J Affect Disord*. 340:312-320.
- Zhou J, et al. 2023. Maternal pregnancy-related anxiety and children's physical growth: the Ma'anshan birth cohort study. *BMC Pregnancy Childbirth*. 23(1):384.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Venlafaxine (Effexor®)

Selected References:

- Alhazmi AM, Albulushi A. 2025. Targeted antihypertensive therapy after hypertensive pregnancy: Lactation-safe choices, treatment thresholds, and outcomes (2015-2025). *Curr Probl Cardiol*. 50(12):103191.
- Bateman BT, et al. 2016. Late pregnancy β Blocker exposure and risks of neonatal hypoglycemia and bradycardia. *Pediatrics*. 138(3):e20160731.
- Beau A-B, et al. 2014. Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database. *BJOG*. 121(7):895-900.
- Berger AA, et al. 2025. Peripartum antihypertensive use and the risk of neonatal hypoglycemia and postpartum uterine atony: a retrospective cohort study. *Pregnancy Hypertens*. 41:101232.
- Caton AR, et al. 2009. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. *Hypertension*. 54(1):63-70.
- Chan WS, et al. 2010. Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. *Hypertens Pregnancy*. 29(3):271-83.
- Clark SM, et al. 2015. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. *Seminars in perinatology*. 39(7):548-555.
- Crooks B, et al. 1998. Adverse neonatal effects of maternal labetalol treatment. *Archives of disease in childhood. Fetal and neonatal edition*. 79(2):F150-F151.
- Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. *Pharmacoepidemiol Drug Saf*. 20(2):138-45.
- Duan L, et al. 2017. β -Blocker exposure in pregnancy and risk of fetal cardiac anomalies. *JAMA Internal Medicine*. 177(6):885-887.
- Firoz T, et al. 2014. Community Level Interventions for Pre-eclampsia (CLIP) Working Group. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. *BJOG*. 121(10):1210-8.
- Freppel R, et al. 2024. Beta-blockers and breastfeeding: a real-life prospective study. *European Journal of Clinical Pharmacology*. 80(12):1937-1943.
- Lam MTC, Dierking E. 2017. Intensive care unit issues in eclampsia and HELLP syndrome. *Int J*

Crit Illn Inj Sci. 7:136-141

- Magee LA, et al. 2022. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. *Pregnancy hypertension*. 27:148-169.
- Magee LA, et al. 2015. Labetalol for hypertension in pregnancy. *Expert Opinion on Drug Safety*. 14(3):453-461.
- Magnus MC, et al. 2021. Risk of miscarriage in women with chronic diseases in Norway: A registry linkage study. *PLoS Med*. 18(5):e1003603.
- Nunez-Pellot C, et al. 2025. Lactation safety of cardiovascular medications. *Am Heart J Plus*. 55:100552.
- O'Meara J, White WB. 1988. Ejaculatory failure and urinary dysfunction secondary to labetalol. *J Urol*. 139:371-2.
- Pasker-de Jong PC, et al. 2010. Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study. *BJOG*. 117(9):1080-6.
- Ramlakhan KP, et al; ROPAC Investigators. 2024. Perinatal outcomes after in-utero exposure to beta-blockers in women with heart disease: Data from the ESC EORP registry of pregnancy and cardiac disease (ROPAC). *Int J Cardiol*. 410:132234.
- Reddy S, Jim B. 2019. Hypertension and pregnancy: Management and future risks. *Advances in Chronic Kidney Disease*. 26(2):137-145.
- Ruys TP, et al. 2014. Cardiac medication during pregnancy, data from the ROPAC. *Int J Cardiol*. 177(1):124-8.
- Tanaka K, et al. 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. *Circ J*. 80(10):2221-6.
- U.S. Food & Drug Administration. (Revised 4/2024). Labetalol hydrochloride drug label. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/018716s036lbl.pdf. [Accessed 1/2026].
- Van Zutphen AR, et al. 2014. Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study. *Obstet Gynecol*. 123:309-317.
- Xie RH, et al. 2014. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. *Eur J Obstet Gynecol Reprod Biol*. 175:124-8.
- Xie RH, et al. 2014. Beta-blockers increase the risk of being born small for gestational age or of being institutionalized during infancy. *BJOG*. 121(9):1090-6.
- Yakoob MY, et al. 2013. The risk of congenital malformations associated with exposure to β -blockers early in pregnancy: a meta-analysis. *Hypertension*. 62(2):375-381.
- Yang X, et al. 2019. Distinct outcomes of labetalol exposed infants: case reports and systematic review. *The Journal of Maternal-Fetal & Neonatal Medicine*. 1-7.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Venlafaxine (Effexor®)

Selected References:

- Bieńkowski CA, et al. 2022. Analysis of preventable risk factors for *Toxoplasma gondii* infection in pregnant women: case-control study. J Clin Med. 11(4):1005.
- Buzby, JC, 2001. Children and Microbial Foodborne Illness. United States Department of Agriculture, Economic Research Service 24(2): 1-6.
- Cavaliere AF, et al. 2023. Case report: vertical transmission of *Plesiomonas shigelloides*. Is it time to strengthen information on safety concerns for raw seafood dietary exposure in pregnancy? J Matern Fetal Neonatal Med. 36(1):2220061.
- Cerisola A, et al. 2025. Congenital toxoplasmosis. Semin Pediatr Neurol. 54:101203.
- Craig AM, et al. 2019. Listeriosis in Pregnancy: A Review. Obstet Gynecol Surv. 74(6):362-368.
- Illinois Department of Public Health. ND. Safe food handling. <https://www.idph.state.il.us/public/hb/hbsafefood.htm/> Accessed 16 June 2026.
- Jeffs E, et al. 2020. The epidemiology of listeriosis in pregnant women and children in New Zealand from 1997 to 2016: an observational study. BMC Public Health. 20(1):116.
- Jones JL. 2011. Sushi in pregnancy, parasitic diseases – obstetrician survey. Zoonoses Public Health. 58(2):119-125.
- Montoya JG, et al 2024. Toxoplasmosis. Lancet. 363(9425):1965-1976.
- New York State Department of Health. 2014. Advice on Eating Game. https://www.health.ny.gov/environmental/outdoors/fish/health_advisories/advice_on_eating_game.htm. Accessed 16 June 2026.
- Oyeyemi OT, et al. 2020. Toxoplasmosis in pregnancy: A neglected bane but a serious threat in Nigeria. Parasitology. 147(2):127-134.
- Quinlan JJ. 2013. Foodborne illness incidence rates and food safety risks for populations of low socioeconomic status and minority race/ethnicity: a review of the literature. Int J Environ Res Public Health. 10(8): 3634-3652.
- U.S. Centers for Disease Control and Prevention (CDC). 2024. About Listeria infection. <https://www.cdc.gov/listeria/about/index.html>. Accessed 16 June 2026.
- U.S. Centers for Disease Control and Prevention (CDC). 2025. About Bacterial Meningitis. <https://www.cdc.gov/meningitis/about/bacterial-meningitis.html>. Accessed 16 June 2026.
- U.S. Centers for Disease Control and Prevention (CDC). 2024. About Salmonella Infection. <https://www.cdc.gov/salmonella/about/index.html>. Accessed 16 June 2026.
- U.S. Centers for Disease Control and Prevention (CDC). 2025. About Toxoplasmosis. <https://www.cdc.gov/toxoplasmosis/about/index.html>. Accessed 16 June 2026.
- U.S. Centers for Disease Control and Prevention (CDC). 2024. About Vibrio infection. <https://www.cdc.gov/vibrio/about/index.html/> Accessed 16 June 2026.
- United States Department of Agriculture (USDA). 2025. Safe Minimum Internal Temperature Chart. <https://www.fsis.usda.gov/food-safety/safe-food-handling-and-preparation/food-safety-basics/safe-temperature-chart>. Accessed 16 June 2026.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Venlafaxine (Effexor®)

Selected References:

- Cazzola M, et al. 2002. Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet, 41(1):19-30.
- Cossette B, et al. 2014. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. Ann Allergy Asthma Immunol, 112(5):459-464.
- GlaxoSmithKline LLC. 2020. Serevent diskus prescribing information.
- Jones KL, et al. 2002. Salmeterol use and pregnancy outcomes: a prospective multi-center study. J Allergy Clin Immunol, 109:S156.
- Lim A, et al. 2011 Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother, 5(7-8):931-945.
- National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. 2025. NAEPP expert panel report: managing asthma during pregnancy—recommendations for pharmacologic treatment—2004 update. J Allergy Clin Immunol, 115(1):34-46.
- Taddio A, Ito S. 2001. Drugs and breast-feeding. In: Koren G, ed. Maternal-fetal toxicology. A clinician's guide. 3rd ed. New York: Marcel Dekker, 177-132.
- Wilton LV, et al. 1998. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol, 105:882-889.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.